PRTA (Prothena Corporation PLC) Market Value to Book Value Ratio
The Prothena Corporation (PRTA) price chart illustrates the asset's dynamics, where success depends directly on the outcomes of drug trials for dementia and Parkinson's, with the current indicator standing at 1.50. The business relies on developing antibodies to eliminate abnormal proteins in the body. Management's high level of expertise in collaborating with global industry behemoths minimizes financial losses and ensures research transparency.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_PRTA_-_Prothena-Corporation_-_Capitalization-to-Book-Value-Ratio "PRTA Prothena Corporation Market Capitalization to Book Value Ratio (07/04/2022 - 10/27/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for prothena.com (PRTA)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Fundamental valuation:PRTA Prothena Corporation PLC
This indicator compares the market value of assets with their book value, identifying speculative overheating of quotes relative to actual capital. The current value of 1.50 in the price action of the market value to book capitalization ratio reflects the high sensitivity of the price to Prothena Corporation (PRTA) clinical test results, where any negative report on Alzheimer's drugs could instantaneously crash the capitalization.
Direct competitors
BIIB: Market Capitalization to Book Value Ratio|NBIX (neurocrine.com) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|BHVN (Biohaven Corp) - Market-to-Book Ratio|Market Value to Book Value Ratio Amylyx Pharmaceuticals AMLX|Market Capitalization to Net Assets TRVI|Praxis Precision Medicines, Inc. (PRAX) - Market Value to Book Value Ratio|Market Value to Book Value AVXL (Anavex)|CBLL: Market Value to Book Value Ratio|ALEC - Market-to-Book Ratio|Market Cap to Net Assets Ratio Annexon, Inc. ANNX|OMER - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio Neurogene NGNE|AC Immune S.A. (ACIU) - Market Value to Book Value|Market Capitalization to Book Value Ratio VYGR (Voyager Pharma)|Market-to-Book Ratio NMRA|Market Value to Book Value Ratio Scilex Holding Company SCLX|Capitalization to Book Value Ratio tevogen.com (TVGN)|Market Capitalization to Book Value Ratio ACOG (Alpha Cognition Inc.)|CGTX - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Inhibikase (IKT)|SAVA - Market Value to Book Value|ASRT (assertiotx.com) - Market Capitalization to Book Value Ratio|COYA (Coya Therapeutics) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio VTGN (VistaGen Therapeutics, Inc.)|Market-to-Book Ratio OVID|Acumen Pharma (ABOS) - Market Value to Book Value Ratio|Market Value to Book Value CRVO (CervoMed Corporation)|Alterity Therapeutics Limited (ATHE) - Market Value to Book Value Ratio|Clene Inc - Market Capitalization to Net Assets|PEPG (PepGen Corp) - Market Value to Book Value Ratio|JUNS: Market-to-Book Ratio|Market Value to Book Value Ratio Relmada RLMD|Annovis Bio Corporation (ANVS) - Market Value to Book Value|GRCE (Grace Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio fireflyneuro.com (AIFF)|Market Cap to Net Assets Ratio Klotho Neurosciences Inc|Market Cap to Book Value Multiple neurosense-tx.com (NRSN)|Market Capitalization to Book Value Ratio RVPH|MetaVia Inc. - Market Capitalization to Book Value|NRXS (NeurAxis, Inc.) - Market Value to Book Value Ratio|HSDT: Market-to-Book Ratio|Market Value to Book Value Ratio passagebio.com|NEUP (Neuphoria Therapeutics) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Minerva Neurosciences Corp NERV|Market Capitalization to Net Assets ATHA|Addex Therapeutics (ADXN) - Market Value to Book Value Ratio|Market Value to Book Value alzamend.com ALZN|Market Cap to Net Assets Ratio Cyclerion Therapeutics, Inc. (CYCN)|Market Cap to Book Value Multiple Protagenic Therapeutics Inc. PTIX|Pasithea - Market Capitalization to Book Value Ratio|CRGT: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Avenue Therapeutics|brainstorm-cell.com (BCLI) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio CARA (Cara Therapeutics)|Market-to-Book Ratio Chromocell Therapeutics Corp (CHRO)|Market Cap to Net Assets Ratio ELYM|Market Capitalization to Book Value Ratio ITCI (intracellulartherapies.com)|Market Value to Book Value Ratio Longboard Pharmaceuticals|marinuspharma.com - Market Value to Book Value|NKGN (NKGen Biotech) - Market Value to Book Value Ratio|NRBO: Market-to-Book Ratio|Market Value to Book Value Ratio Sage Therapeutics, Inc (SAGE)|SNPX (Synaptogenix, Inc) - Market Capitalization to Net Assets|TRVN - Market Value to Book Value Ratio|Market Value to Book Value VIGL|Anew Medical, Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio Cerevel Therapeutics Inc CERE